Which has better earnings and valuation, ANRO or DYN?

Alto Neuroscience is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alto Neuroscience N/A N/A -$63.24M -$2.42 N/A Dyne Therapeutics N/A N/A -$446.21M -$3.22 N/A

Is ANRO or DYN more profitable?

Alto Neuroscience's return on equity of -47.22% beat Dyne Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Alto Neuroscience N/A -47.22% -38.81% Dyne Therapeutics N/A -58.28% -46.77%

Is ANRO or RLAY more profitable?

Relay Therapeutics' return on equity of -43.94% beat Alto Neuroscience's return on equity. Company Net Margins Return on Equity Return on Assets Alto Neuroscience N/A -47.22% -38.81% Relay Therapeutics N/A -43.94% -40.11%

Which has higher valuation & earnings, GPCR or ANRO?

Structure Therapeutics is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Structure Therapeutics N/A N/A -$141.20M -$0.87 N/A Alto Neuroscience N/A N/A -$63.24M -$2.42 N/A

Is GPCR or ANRO more profitable?

Structure Therapeutics' return on equity of -24.91% beat Alto Neuroscience's return on equity. Company Net Margins Return on Equity Return on Assets Structure Therapeutics N/A -24.91% -23.67% Alto Neuroscience N/A -47.22% -38.81%

Alto Neuroscience (ANRO) Competitors

$26.84 -0.21 (-0.76%)

Closing price 06/26/2026 03:59 PM Eastern

Extended Trading

$26.35 -0.48 (-1.80%)

As of 05:27 AM Eastern

Compare

ANRO vs. BEAM, DYN, RLAY, ARQT, and GPCR

Should you buy Alto Neuroscience stock or one of its competitors? MarketBeat compares Alto Neuroscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alto Neuroscience include Beam Therapeutics (BEAM), Dyne Therapeutics (DYN), Relay Therapeutics (RLAY), Arcutis Biotherapeutics (ARQT), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical products" industry.

How does Alto Neuroscience compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Alto Neuroscience (NYSE:ANRO) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

99.7% of Beam Therapeutics shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by company insiders. Comparatively, 11.3% of Alto Neuroscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Beam Therapeutics currently has a consensus price target of $46.83, suggesting a potential upside of 34.53%. Alto Neuroscience has a consensus price target of $35.25, suggesting a potential upside of 31.36%. Given Beam Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Beam Therapeutics is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Alto Neuroscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

In the previous week, Beam Therapeutics had 6 more articles in the media than Alto Neuroscience. MarketBeat recorded 6 mentions for Beam Therapeutics and 0 mentions for Alto Neuroscience. Beam Therapeutics' average media sentiment score of 0.73 beat Alto Neuroscience's score of 0.00 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Beam Therapeutics	Positive
Alto Neuroscience	Neutral

Alto Neuroscience has a net margin of 0.00% compared to Beam Therapeutics' net margin of -39.66%. Beam Therapeutics' return on equity of -29.00% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
Alto Neuroscience	N/A	-47.22%	-38.81%

Alto Neuroscience has lower revenue, but higher earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	25.63	-$79.99M	-$0.68	N/A
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A

Beam Therapeutics has a beta of 2.25, meaning that its stock price is 125% more volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market.

Summary

Beam Therapeutics beats Alto Neuroscience on 12 of the 16 factors compared between the two stocks.

How does Alto Neuroscience compare to Dyne Therapeutics?

Alto Neuroscience (NYSE:ANRO) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Alto Neuroscience is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A

Alto Neuroscience has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market.

Alto Neuroscience currently has a consensus target price of $35.25, suggesting a potential upside of 31.36%. Dyne Therapeutics has a consensus target price of $34.17, suggesting a potential upside of 63.16%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Dyne Therapeutics is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

In the previous week, Dyne Therapeutics had 13 more articles in the media than Alto Neuroscience. MarketBeat recorded 13 mentions for Dyne Therapeutics and 0 mentions for Alto Neuroscience. Dyne Therapeutics' average media sentiment score of 0.02 beat Alto Neuroscience's score of 0.00 indicating that Dyne Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Alto Neuroscience	Neutral
Dyne Therapeutics	Neutral

Alto Neuroscience's return on equity of -47.22% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-47.22%	-38.81%
Dyne Therapeutics	N/A	-58.28%	-46.77%

96.7% of Dyne Therapeutics shares are held by institutional investors. 11.3% of Alto Neuroscience shares are held by company insiders. Comparatively, 9.5% of Dyne Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Dyne Therapeutics beats Alto Neuroscience on 8 of the 14 factors compared between the two stocks.

How does Alto Neuroscience compare to Relay Therapeutics?

Alto Neuroscience (NYSE:ANRO) and Relay Therapeutics (NASDAQ:RLAY) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

Alto Neuroscience has higher earnings, but lower revenue than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A
Relay Therapeutics	$15.35M	231.66	-$276.48M	-$1.57	N/A

Alto Neuroscience presently has a consensus target price of $35.25, suggesting a potential upside of 31.36%. Relay Therapeutics has a consensus target price of $23.30, suggesting a potential upside of 25.54%. Given Alto Neuroscience's higher possible upside, research analysts clearly believe Alto Neuroscience is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Relay Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

Alto Neuroscience has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market.

97.0% of Relay Therapeutics shares are owned by institutional investors. 11.3% of Alto Neuroscience shares are owned by company insiders. Comparatively, 5.0% of Relay Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Relay Therapeutics had 6 more articles in the media than Alto Neuroscience. MarketBeat recorded 6 mentions for Relay Therapeutics and 0 mentions for Alto Neuroscience. Relay Therapeutics' average media sentiment score of 0.18 beat Alto Neuroscience's score of 0.00 indicating that Relay Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Alto Neuroscience	Neutral
Relay Therapeutics	Neutral

Relay Therapeutics' return on equity of -43.94% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-47.22%	-38.81%
Relay Therapeutics	N/A	-43.94%	-40.11%

Summary

Relay Therapeutics beats Alto Neuroscience on 9 of the 14 factors compared between the two stocks.

How does Alto Neuroscience compare to Arcutis Biotherapeutics?

Alto Neuroscience (NYSE:ANRO) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

Alto Neuroscience has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -0.57%. Arcutis Biotherapeutics' return on equity of -1.41% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-47.22%	-38.81%
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%

Alto Neuroscience presently has a consensus price target of $35.25, indicating a potential upside of 31.36%. Arcutis Biotherapeutics has a consensus price target of $34.00, indicating a potential upside of 25.93%. Given Alto Neuroscience's stronger consensus rating and higher probable upside, analysts clearly believe Alto Neuroscience is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Alto Neuroscience has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market.

Arcutis Biotherapeutics has higher revenue and earnings than Alto Neuroscience. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A
Arcutis Biotherapeutics	$376.07M	8.98	-$16.14M	-$0.03	N/A

In the previous week, Arcutis Biotherapeutics had 4 more articles in the media than Alto Neuroscience. MarketBeat recorded 4 mentions for Arcutis Biotherapeutics and 0 mentions for Alto Neuroscience. Arcutis Biotherapeutics' average media sentiment score of 0.89 beat Alto Neuroscience's score of 0.00 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Alto Neuroscience	Neutral
Arcutis Biotherapeutics	Positive

Summary

Arcutis Biotherapeutics beats Alto Neuroscience on 8 of the 13 factors compared between the two stocks.

How does Alto Neuroscience compare to Structure Therapeutics?

Structure Therapeutics (NASDAQ:GPCR) and Alto Neuroscience (NYSE:ANRO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings.

In the previous week, Structure Therapeutics had 1 more articles in the media than Alto Neuroscience. MarketBeat recorded 1 mentions for Structure Therapeutics and 0 mentions for Alto Neuroscience. Structure Therapeutics' average media sentiment score of 1.87 beat Alto Neuroscience's score of 0.00 indicating that Structure Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Structure Therapeutics	Very Positive
Alto Neuroscience	Neutral

Structure Therapeutics currently has a consensus price target of $110.55, suggesting a potential upside of 122.38%. Alto Neuroscience has a consensus price target of $35.25, suggesting a potential upside of 31.36%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Structure Therapeutics is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89
Alto Neuroscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Structure Therapeutics' return on equity of -24.91% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-24.91%	-23.67%
Alto Neuroscience	N/A	-47.22%	-38.81%

Structure Therapeutics has a beta of -1.35, suggesting that its stock price is 235% less volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market.

Structure Therapeutics is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A

91.8% of Structure Therapeutics shares are owned by institutional investors. 5.5% of Structure Therapeutics shares are owned by company insiders. Comparatively, 11.3% of Alto Neuroscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Structure Therapeutics beats Alto Neuroscience on 10 of the 14 factors compared between the two stocks.

Get Alto Neuroscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANRO vs. The Competition

Export

Metric	Alto Neuroscience	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$941.64M	$3.62B	$6.83B	$23.30B
Dividend Yield	N/A	2.21%	2.66%	4.08%
P/E Ratio	-11.09	21.75	25.91	31.64
Price / Sales	N/A	340.46	548.81	20.93
Price / Cash	N/A	62.10	29.09	18.60
Price / Book	5.51	8.31	10.82	4.75
Net Income	-$63.24M	$23.92M	$3.58B	$1.07B
7 Day Performance	17.03%	1.93%	1.90%	1.36%
1 Month Performance	33.36%	-0.41%	-0.26%	0.70%
1 Year Performance	1,044.35%	65.22%	34.40%	25.30%

Alto Neuroscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANRO Alto Neuroscience	1.9564 of 5 stars	$26.84 -0.8%	$35.25 +31.4%	+1,044.3%	$941.64M	N/A	N/A	N/A	Gap Down High Trading Volume
BEAM Beam Therapeutics	2.1954 of 5 stars	$33.20 -6.6%	$46.83 +41.1%	+107.2%	$3.42B	$164.01M	N/A	510
DYN Dyne Therapeutics	2.549 of 5 stars	$20.26 -2.9%	$33.85 +67.1%	+118.8%	$3.35B	N/A	N/A	100	Analyst Forecast Insider Trade
RLAY Relay Therapeutics	2.9413 of 5 stars	$17.44 +0.9%	$23.30 +33.6%	+462.4%	$3.34B	$15.35M	N/A	330	Gap Down
ARQT Arcutis Biotherapeutics	3.3247 of 5 stars	$26.27 -1.5%	$34.00 +29.4%	+96.5%	$3.29B	$376.07M	N/A	150

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ANRO) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alto Neuroscience (ANRO) Competitors

ANRO vs. BEAM, DYN, RLAY, ARQT, and GPCR

How does Alto Neuroscience compare to Beam Therapeutics?

Summary

How does Alto Neuroscience compare to Dyne Therapeutics?

Summary

How does Alto Neuroscience compare to Relay Therapeutics?

Summary

How does Alto Neuroscience compare to Arcutis Biotherapeutics?

Summary

How does Alto Neuroscience compare to Structure Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANRO vs. The Competition

Alto Neuroscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alto Neuroscience (ANRO) Competitors

ANRO vs. BEAM, DYN, RLAY, ARQT, and GPCR

How does Alto Neuroscience compare to Beam Therapeutics?

Do institutionals & insiders have more ownership in BEAM or ANRO?

Do analysts prefer BEAM or ANRO?

Does the media refer more to BEAM or ANRO?

Is BEAM or ANRO more profitable?

Which has higher earnings & valuation, BEAM or ANRO?

Which has more risk and volatility, BEAM or ANRO?

Summary

How does Alto Neuroscience compare to Dyne Therapeutics?

Which has better earnings and valuation, ANRO or DYN?

Which has more volatility and risk, ANRO or DYN?

Do analysts prefer ANRO or DYN?

Does the media favor ANRO or DYN?

Is ANRO or DYN more profitable?

Do insiders & institutionals hold more shares of ANRO or DYN?

Summary

How does Alto Neuroscience compare to Relay Therapeutics?

Which has preferable earnings and valuation, ANRO or RLAY?

Do analysts recommend ANRO or RLAY?

Which has more risk & volatility, ANRO or RLAY?

Do institutionals & insiders hold more shares of ANRO or RLAY?

Does the media favor ANRO or RLAY?

Is ANRO or RLAY more profitable?

Summary

How does Alto Neuroscience compare to Arcutis Biotherapeutics?

Is ANRO or ARQT more profitable?

Do analysts prefer ANRO or ARQT?

Which has more risk & volatility, ANRO or ARQT?

Which has stronger valuation & earnings, ANRO or ARQT?

Does the media refer more to ANRO or ARQT?

Summary

How does Alto Neuroscience compare to Structure Therapeutics?

Does the media refer more to GPCR or ANRO?

Do analysts prefer GPCR or ANRO?

Is GPCR or ANRO more profitable?

Which has more volatility & risk, GPCR or ANRO?

Which has higher valuation & earnings, GPCR or ANRO?

Do institutionals & insiders have more ownership in GPCR or ANRO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANRO vs. The Competition

Alto Neuroscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools